Growing Popularity as Defensive Stock

0
210

We just covered the 14 Best Defensive Stocks to Invest In Now and Gilead Sciences, Inc. (NASDAQ:GILD) ranks 4th on this list.

Gilead Sciences, Inc. (NASDAQ:GILD) has transitioned away from its volatile COVID-19 treatment revenue from Veklury. The core business in HIV and a growing oncology pipeline provide the firm with high-visibility, non-discretionary earnings. The defensive strength is the dominant position in the HIV market, which functions similarly to a utility because the treatments are life-sustaining and non-discretionary. Gilead’s HIV portfolio generated $20.8 billion in 2025. Patients rarely switch treatments once stabilized, creating a highly predictable cash flow that is unaffected by broader economic cycles. During the Barclays Healthcare Conference in March, CFO Andrew Dickinson emphasized that Gilead faces no major loss of exclusivity until 2036. This runway…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here